Cargando…
Second-Generation Pharmacological Chaperones: Beyond Inhibitors
Protein misfolding induced by missense mutations is the source of hundreds of conformational diseases. The cell quality control may eliminate nascent misfolded proteins, such as enzymes, and a pathological loss-of-function may result from their early degradation. Since the proof of concept in the 20...
Autores principales: | Tran, My Lan, Génisson, Yves, Ballereau, Stéphanie, Dehoux, Cécile |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397201/ https://www.ncbi.nlm.nih.gov/pubmed/32660097 http://dx.doi.org/10.3390/molecules25143145 |
Ejemplares similares
-
Pharmacological Chaperone Therapy for Pompe Disease
por: Borie-Guichot, Marc, et al.
Publicado: (2021) -
Selective Targeting of the Interconversion between Glucosylceramide and Ceramide by Scaffold Tailoring of Iminosugar Inhibitors
por: Baudoin-Dehoux, Cécile, et al.
Publicado: (2019) -
Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from Mycobacterium tuberculosis: A Crystallographic and Molecular Modelling Study
por: Galy, Romain, et al.
Publicado: (2021) -
Galactosemia: Towards Pharmacological Chaperones
por: Banford, Samantha, et al.
Publicado: (2021) -
Azasugar inhibitors as pharmacological chaperones for Krabbe disease
por: Hill, Chris H., et al.
Publicado: (2015)